General form of registration statement for all companies including face-amount certificate companies

SHAREHOLDERS' DEFICIT - Additional Information (Details)

v3.24.1.1.u2
SHAREHOLDERS' DEFICIT - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 16, 2023
Aug. 31, 2023
shares
Jun. 30, 2023
shares
May 31, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Aug. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
May 14, 2024
shares
Sep. 30, 2022
shares
Jun. 09, 2021
$ / shares
shares
Apr. 30, 2020
$ / shares
SHAREHOLDERS' EQUITY (DEFICIT)                            
Common stock, shares authorized         9,000,000   9,000,000 9,000,000 9,000,000 9,000,000 250,000,000 180,000,000    
Common stock, par value (in dollars per share) | $ / shares         $ 0.001   $ 0.001 $ 0.001 $ 0.001 $ 0.001        
Common stock, shares issued             8,326,589   6,720,460 1,051,098        
Common stock, shares outstanding             8,326,589   6,720,460 1,051,098        
Holders of number of shares of common stock present and approved for increase of authorized shares                     5,427,462      
Period to submit plan to regain compliance 45 days                          
Proceeds from share issuance, net of share issuance costs | $               $ 300,000 $ 5,383,000 $ 5,195,000        
Price per share | $ / shares       $ 1.20                    
Pre-funded warrants       750,000                    
Pre-funded warrants, shares   750,000                        
Warrant exercise price (in dollars per share) | $ / shares                         $ 1.20 $ 100.00
Stock-based compensation (in shares)             268,758              
General corporate purposes, including working capital, marketing, and capital expenditures | $                 5,100,000          
Common shares to certain employees, directors and vendors in lieu of cash compensation     59,748                      
Reverse stock split ratio         0.05                  
Fractional shares issued         0                  
Gross proceeds | $               $ 300,000 $ 5,383,000 $ 5,195,000        
Common share purchase warrants per unit                         1  
Convertible Debt                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Common shares issued to settle amounts owed | $             1,337,371              
Debt repaid | $             $ 334,000              
Debt Instrument, Convertible, Settlement Method [Extensible Enumeration]             us-gaap:ShareSettlementMember              
Amended Stock Option Plan                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Common stock, shares outstanding             19,555   24,925          
Equity Incentive Plan                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Common stock, shares outstanding             1,500   11,500          
Number of shares authorized             98,500   88,500          
Private Placements                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Shares issued         50,000   50,000              
Gross proceeds | $             $ 300,000              
Shares issue price | $ / shares         $ 6.00   $ 6.00 $ 6.00            
Gross proceeds | $         $ 300,000                  
Public offering (pre-funded warrants)                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Shares issued       5,000,000                    
Price per share | $ / shares       $ 1.199                    
Warrant exercise price (in dollars per share) | $ / shares       $ 0.001                    
Gross proceeds | $       $ 6,000,000                    
Option to purchase additional shares                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Shares issued       750,000                    
Number of days to purchase additional shares       45 days                    
Additional shares issued under allotment       0                    
2022 Equity Financing                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Proceeds from share issuance, net of share issuance costs | $           $ 6,200,000                
Shares issued           278,804                
Period to purchase additional shares           45 days                
Percentage of additional shares issued           15.00%                
Shares issue price | $ / shares           $ 22.40                
Acquisition of Certain Assets of Innovation Neuromonitoring, LLC                            
SHAREHOLDERS' EQUITY (DEFICIT)                            
Share issuance, acquisition related (in shares)   547,946